Companies who are fighting the scourge of cancer and other diseases deserve the attention they are receiving.
Wednesday, it was the turn of Laguna Beach, Calif.-based PharmaCyte Biotech, Inc. (OTC:PMCB) to shine, with word both batches of the company’s manufactured clinical trial product have undergone and passed all 10 of the necessary “release tests” required by the U.S. Food and Drug Administration (FDA).
PMCB isa biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology.
CEO Kenneth Waggoner said, "After completing the production of our clinical trial product, it is extremely good news to learn that our capsules and the live cells inside are functioning and safe to put inside patients in our upcoming planned clinical trial in locally advanced, inoperable pancreatic cancer.
"There were 20 tests in total over both batches, and our clinical trial product passed all of them. This proves that our years of hard work and working through each challenging hurdle (were) well worth it."
Shares in PMCB sprang 11.7% to 5.45 cents near the end of Wednesday’s session, on volume topping 5.9 million shares.
